Antiretroviral-treated HIV-1 patients can harbour resistant viruses in CSF despite an undetectable viral load in plasma.
Fiche publication
Date publication
mai 2017
Journal
The Journal of antimicrobial chemotherapy
Auteurs
Membres identifiés du Cancéropôle Est :
Dr JEULIN Hélène
Tous les auteurs :
Soulie C, Grudé M, Descamps D, Amiel C, Morand-Joubert L, Raymond S, Pallier C, Bellecave P, Reigadas S, Trabaud MA, Delaugerre C, Montes B, Barin F, Ferré V, Jeulin H, Alloui C, Yerly S, Signori-Schmuck A, Guigon A, Fafi-Kremer S, Haïm-Boukobza S, Mirand A, Maillard A, Vallet S, Roussel C, Assoumou L, Calvez V, Flandre P, Marcelin AG,
Lien Pubmed
Résumé
HIV therapy reduces the CSF HIV RNA viral load (VL) and prevents disorders related to HIV encephalitis. However, these brain disorders may persist in some cases. A large population of antiretroviral-treated patients who had a VL > 1.7 log 10 copies/mL in CSF with detectable or undetectable VL in plasma associated with cognitive impairment was studied, in order to characterize discriminatory factors of these two patient populations.
Mots clés
Adult, Anti-Retroviral Agents, therapeutic use, Cerebrospinal Fluid, virology, Drug Resistance, Viral, Female, France, Genotype, Genotyping Techniques, HIV Infections, drug therapy, HIV-1, genetics, Humans, Male, Microbial Sensitivity Tests, Middle Aged, Plasma, virology, Retrospective Studies, Switzerland, Viral Load
Référence
J. Antimicrob. Chemother.. 2017 May;: